Patients Pay The Bill For Delaying Hip Replacement

Published Jan 17, 2013
Exeter, UK –Research has shown that primary total hip replacement (THR) has reduced pain and improved mobility and functioning in patients with severe osteoarthritis. Some reports suggest, however, that most eligible patients, women in particular, undergo THR with delay. A study, “Cost-Effectiveness Analysis of Early versus Late Total Hip Replacement in Italy,” published in Value in Health, is the first study to estimate the costs and health benefits of delaying surgery from the health system’s perspective and, incidentally, to offer an explanation for women’s delayed timing of THR relative to men. The model-based assessment demonstrated that delaying THR until the patient’s functional ability was compromised represented a loss in quality of life equivalent to 3.5 years of full health and only saved the Italian National Health System €1,800 (i.e. €534 per QALY gained with early THR) over the course of the patients’ lifetime. Early THR costs more than delayed THR, but resulted in significant benefits in terms of quality of life and only marginally more risk in terms of implant failure late in life. While this study shows that delaying THR is not cost-effective based on Italian cost data, these findings raise the question of whether similar conclusions apply to other health systems. Dr. Ruben Mujica-Mota, PhD, author of the study, states: "This research clearly suggests that the cost savings to national health systems in Europe brought about by delaying THR may not justify the large quality of life losses to patients. It also suggests that early THR would be less cost-effective in women than men if quality of life gains with surgery are proven to erode over time. This is because women would experience more low quality of life years than men due to the fact that women live longer. While this scenario may be consciously motivating doctors to delay surgery in women, more research is needed to measure the long term health benefits of THR."

Value in Health (ISSN 1098-3015) publishes papers, concepts, and ideas that advance the field of pharmacoeconomics and outcomes research as well as policy papers to help health care leaders make evidence-based decisions. The journal is published bi-monthly and has over 8,000 subscribers (clinicians, decision makers, and researchers worldwide).

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a nonprofit, international, educational and scientific organization that strives to increase the efficiency, effectiveness, and fairness of health care resource use to improve health.

For more information: www.ispor.org

Related Stories

The Ozempic Paradox: How Spending Billions on Weight-Loss Drug Would Actually Reduce Overall Medicare Costs

Oct 14, 2025

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a landmark study by researchers at the University of Washington, Curta, Inc, and the University of North Carolina showing that broad Medicare coverage of semaglutide in diabetes, obesity, and liver disease could generate significant cost savings while delivering substantial health benefits to beneficiaries. The report, “Comprehensive Access to Semaglutide: Clinical and Economic Implications for Medicare,” was published in the October 2025 issue of Value in Health.

ISPOR Launches New Content on Whole Health

Sep 23, 2025

ISPOR announced that it has launched new website content on whole health, a topic of increasing importance as health systems across the globe grapple with providing the best possible healthcare to patients within constrained budgets.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×